Will Asana's stock-based compensation fall below 25% of revenue for any quarter in FY2027?

The Q4 FY2026 data confirms the SBC decline trend is intact — non-GAAP operating margin expanded to 9%, indicating continued cost discipline. However, FY2027 revenue guidance of $854M is lower than the pre-earnings ~$870M assumption, shrinking the denominator. If FY2026 SBC came in at ~$213M (~27% of $790M) and the ~2pp/year decline continues, FY2027 full-year SBC% would be ~25%. Q3/Q4 FY2027, with stronger revenue seasonality and back-loaded SBC amortization trailing off from earlier grant cycles, could push one quarter below 25%. The $200M buyback doesn't directly reduce SBC expense but signals management focus on shareholder-friendly capital allocation, possibly constraining new equity grants.

The stock price at $7.60 is a meaningful headwind. Equity comp grants are denominated in dollars but expensed based on share count times grant-date fair value. At $7.60 vs. a higher price, each dollar of target compensation requires more shares, and if new grants are made at this depressed price, the per-share SBC expense is the same but the share count is higher. More critically, the FY2027 revenue guidance midpoint of $854M represents only 8% growth — slower than the 9% FY2026 growth. This decelerating revenue growth means the denominator is expanding less quickly. Combined with Rogers' equity grants ($35M over 3 years) still amortizing, the math for reaching sub-25% in any single quarter is tighter than pre-earnings estimates suggested.

I weight the quarterly timing dimension more heavily. The question asks about ANY quarter, not the full year. If FY2027 annual SBC% is approximately 25-26%, then a back-half quarter (Q3 or Q4) with stronger revenue and trailing SBC recognition from maturing grant cohorts has a meaningful chance of dipping below 25%. The company's restructuring actions have reduced headcount to ~1,819, and the Warsaw labor arbitrage suggests new hires may receive lower equity comp than departing higher-cost employees. Q4 FY2027 (January 2027 quarter) would benefit from the strongest seasonal revenue plus full-year cost discipline. The resolved sibling markets show our ensemble has been well-calibrated on ASAN operational metrics (enterprise growth and RPO were correct), suggesting the underlying trend assessment is sound.

The Q4 earnings update introduces two offsetting forces. On the positive side, 9% non-GAAP operating margin and 13% FCF margin confirm real operational leverage is emerging. On the negative side, FY2027 revenue guidance of $854M (vs prior ~$870M assumption) directly reduces the denominator in SBC/revenue. At $854M revenue and projected ~$220M SBC, FY2027 annual SBC% would be ~25.8% — further from the threshold than pre-earnings. The $7.60 stock price is a subtle but important headwind: RSU and PSU grants vest in shares, and if the company needs to grant more shares to deliver the same dollar compensation, ASC 718 expense could increase. Management has not signaled any intent to reduce SBC as a strategic priority.

Balancing the new data: the earnings update is roughly neutral for this market. The lower revenue guidance (~$854M vs ~$870M) is a headwind, but the continued margin expansion and cost discipline suggest SBC growth is being contained. The 2pp/year decline in SBC% has been remarkably consistent over three years (34.5% to 31.0% to 29.2%), and there is no specific evidence it has broken down — FY2026 results (10-K pending) should confirm whether FY2026 SBC% landed near the projected ~27%. If it did, the trend projects to ~25% annual for FY2027, with quarterly variance creating a plausible path for one quarter to dip below. I maintain roughly the same probability as the initial ensemble.

I focus on the risk factors that have intensified since the initial prediction. First, the stock at $7.60 is near multi-year lows — at this price, any retention-driven equity refreshes or new hire grants would require substantially more shares, increasing SBC expense. Second, revenue growth is decelerating (9% FY2026, guided 7.5-8.5% FY2027), meaning the denominator improvement is slowing. Third, the AI Teammates initiative is being positioned as a growth driver, which typically requires investment (engineering hires with equity comp). The resolved sibling market for AI revenue disclosure resolved YES with a major miss (Brier 0.7569), suggesting our models may underweight how aggressively Asana is investing in AI — which would add SBC through new hires and equity refreshes.

The 2pp/year SBC decline trend projects to ~25% annual for FY2027, but the lower revenue guidance ($854M vs $870M) makes the per-quarter math tighter. At $854M and ~$220M SBC, full-year is ~25.8%. Q4 FY2027 revenue of ~$225M with quarterly SBC of ~$55M yields ~24.4% — possible but requires strong Q4 execution. Lower stock price is a headwind for new grant pricing. Net assessment: slightly below initial 33%.

The $200M buyback authorization is a modest positive signal — it shows the board is shifting from pure equity dilution toward returning capital. This cultural shift at the board level could translate into more restrained new equity grant programs. However, the buyback primarily reduces diluted share count rather than SBC expense directly. The continued non-GAAP margin expansion (9% in Q4) confirms operating leverage is real. Four quarterly chances at sub-25% with a projected annual average near 25-26% gives roughly 1-in-3 odds, consistent with the initial estimate.

Revenue growth deceleration is the key new negative signal. Going from 9% growth (FY2026) to 7.5-8.5% (FY2027 guided) means each quarterly revenue figure is lower than previously assumed. For SBC as a percentage of revenue, a smaller denominator makes reaching 25% harder. Combined with the stock price headwind at $7.60 and no explicit management commentary about SBC reduction, I lean slightly below the initial 33% estimate. The buyback is insufficient to offset these headwinds in SBC expense terms.